Literature DB >> 18689985

The Beck Depression Inventory requires modification in scoring before use in a haemodialysis population in the UK.

Donna Grant1, Michael K Almond, Alison Newnham, Pauline Roberts, Andrew Hutchings.   

Abstract

BACKGROUND: There are high rates of mental illness, especially depression in people with end-stage renal disease (ESRD) on haemodialysis (HD). Depression can be difficult to diagnose, as depression and the medical problem share many symptoms. It is essential that the diagnosis of a depressive illness be accurately made in order that subsequent psychiatric management can occur. This is the first study done in the UK which aims to validate a simple method for detecting depression, the Beck Depression Inventory (BDI), in people on HD against a structured psychiatric interview with a trained psychiatrist using the ICD-10 classification of depression. The BDI is validated in a normal population, but in patients with physical ill health there has been a difficulty in defining appropriate cut-off scores.
METHODS: Patients dialysing for over 3 months from a single HD unit were eligible for participation. Patients were excluded if a known psychiatric illness existed or if they were receiving medication for a psychiatric illness. Patients who had a recent major illness requiring hospitalisation were excluded. 57 consenting participants completed the self-reported BDI. Within the next week a psychiatrist carried out a clinical interview to diagnose depression, based on the ICD-10 classification of a depressive disorder. Patients were classified as not being depressed or having mild, moderate or severe depression according to their BDI score or the ICD-10 classification.
RESULTS: The BDI gave more scores for depression and more severe scores than ICD-10. 30 cases had scores which agreed, 27 cases resulted in a higher BDI score than the ICD-10 classification, in no case was the ICD-10 classification more severe (Wilcoxon signed rank test p < 0.001). All 7 diagnosed as being depressed by clinical interview were also depressed by BDI, although in 2 cases the BDI worsened the depression score.
CONCLUSIONS: Using the general population cut-off score, the BDI significantly overdiagnosed depression in this HD population. This study defines a BDI cut-off score which more reliably detects major depression in a HD population. Unrecognised depression remains high in those with no known psychiatric illness within the HD populations. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18689985     DOI: 10.1159/000151230

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  6 in total

1.  Validity of the Beck Depression Inventory as a screening tool for a clinical mood disorder in bariatric surgery candidates.

Authors:  Melissa J Hayden; Wendy A Brown; Leah Brennan; Paul E O'Brien
Journal:  Obes Surg       Date:  2012-11       Impact factor: 4.129

2.  Depression in hemodialysis patients.

Authors:  Badema Cengić; Halima Resić
Journal:  Bosn J Basic Med Sci       Date:  2010-04       Impact factor: 3.363

3.  Depression, quality of life, and medical resource utilization in sickle cell disease.

Authors:  Soheir S Adam; Charlene M Flahiff; Shital Kamble; Marilyn J Telen; Shelby D Reed; Laura M De Castro
Journal:  Blood Adv       Date:  2017-10-12

4.  Depression, insomnia and sleep apnea in patients on maintenance hemodialysis.

Authors:  M Rai; T Rustagi; S Rustagi; R Kohli
Journal:  Indian J Nephrol       Date:  2011-10

5.  Depression Screening Tools for Patients with Kidney Failure: A Systematic Review.

Authors:  Karli Kondo; Jennifer R Antick; Chelsea K Ayers; Devan Kansagara; Pavan Chopra
Journal:  Clin J Am Soc Nephrol       Date:  2020-11-17       Impact factor: 8.237

6.  Depression in hemodialysis patients: the role of dialysis shift.

Authors:  Flavio Teles; Vega Figueiredo Dourado de Azevedo; Claudio Torres de Miranda; Milma Pires de Melo Miranda; Maria do Carmo Teixeira; Rosilene M Elias
Journal:  Clinics (Sao Paulo)       Date:  2014-03       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.